Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | INT230-6 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INT230-6 | INT 230-6|INT-230-6 | INT230-6 is a therapy comprised of cisplatin and vinblastine plus a cell penetration excipient, which leads to improved uptake of the drug into cancer cells, potentially resulting in tumor regression as well as indirect antitumor effects (Cancer Res 2015;75(15 Suppl):Abstract nr 4295, PMID: 31646070). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03058289 | Phase Ib/II | INT230-6 INT230-6 + unspecified PD-1 antibody | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) | Completed | USA | CAN | 0 |